Togo Y, Schwartz A R, Hornick R B
Antimicrob Agents Chemother. 1973 Dec;4(6):612-6. doi: 10.1128/AAC.4.6.612.
Double-blind trials were conducted in volunteers to evaluate the efficacy of the prophylactic 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA) treatment against rhinovirus type 24 challenge. Ten men received a 7-day course of DIQA treatment and 11 men received a placebo. The intranasal viral challenge dose was 10 mean tissue culture infective doses. The oral administration of 1 g prechallenge and 2 g a day for 6 consecutive postchallenge days did not prevent the development of colds. Nine drug-treated men and 10 controls developed rhinovirus illness. However, the illnesses of the drug-treated men were mild. Rhinorrhea occurred less frequently and was more mild in the drug-treated group. The challenge virus was recovered from 80% of these subjects in both groups, but almost twice the number of challenge viruses were isolated from the controls than from the drug-treated men. The prophylactic DIQA therapy appears to suppress the cold syndrome and to reduce virus excretion, although its effect is marginal. Additional clinical trials are warranted to confirm the antirhinoviral effect of this drug.
在志愿者中进行了双盲试验，以评估预防性使用盐酸3,4 - 二氢 - 1 - 异喹啉乙酰胺（DIQA）治疗抵抗24型鼻病毒攻击的疗效。10名男性接受了为期7天的DIQA治疗疗程，11名男性接受了安慰剂治疗。鼻内病毒攻击剂量为10个平均组织培养感染剂量。在攻击前口服1克，攻击后连续6天每天口服2克，并不能预防感冒的发生。9名接受药物治疗的男性和10名对照组出现了鼻病毒疾病。然而，接受药物治疗的男性的疾病症状较轻。在药物治疗组中，流鼻涕的发生频率较低且症状较轻。两组中80%的受试者都检测到了攻击病毒，但从对照组分离出的攻击病毒数量几乎是药物治疗组的两倍。预防性DIQA治疗似乎能抑制感冒症状并减少病毒排泄，尽管其效果有限。有必要进行更多的临床试验来证实这种药物的抗鼻病毒作用。
